Manufacturing

Our efforts to organize a well-controlled process of creating a broad portfolio of high-quality and effective medications has not gone unrewarded. We have developed a new manufacturing strategy combining in-house and partner-controlled production facilities which comply with EU GMP standards.

Our efforts to organize a well-controlled process of creating a broad portfolio of high-quality and effective medications has not gone unrewarded. We have developed a new manufacturing strategy combining in-house and partner-controlled production facilities which comply with EU GMP standards. In close cooperation with fraternal companies, we continually monitor the manufacturing process and the quality of API in both our own and in contracted production facilities, exchanging know-how with the aim of improving technologies and optimizing business processes. Over the last year we have conducted:

  • more than 300 inspections of production facilities;
  • more than 1000 tests of API batches.

A key aspect of our manufacturing strategy is the continuous upgrading and extension of assets. This enables us to adhere to the highest industry and environmental standards, and control the cost of production, resulting in products that are affordable in developing nations.